NEW YORK (GenomeWeb News) – Trilink BioTechnologies said today that it has inked a new licensing agreement with Biofortuna allowing the UK firm to use Trilink's hot start deoxynucleotides for freeze-drying molecular diagnostic kit development and production service.

Biofortuna offers this product to "diagnostic companies looking to develop stabilized molecular diagnostic kits," said Mike Bunce, chief science officer of Biofortuna, in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.